Analyst Price Targets — SOPH
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 15, 2026 10:36 am | — | BTIG | $8.00 | $4.96 | TheFly | Sophia Genetics price target raised to $8 from $7 at BTIG |
| March 3, 2026 7:23 pm | Mark Massaro | BTIG | $7.00 | $4.10 | StreetInsider | BTIG Reiterates Buy Rating on Sophia Genetics SA (SOPH) |
| January 26, 2026 2:36 pm | — | Guggenheim | $7.00 | $5.35 | TheFly | Sophia Genetics price target raised to $7 from $6 at Guggenheim |
| March 6, 2025 12:11 pm | — | BTIG | $5.00 | $3.11 | TheFly | Sophia Genetics price target lowered to $5 from $6 at BTIG |
| August 7, 2024 11:35 am | Tejas Savant | Morgan Stanley | $5.00 | $3.92 | TheFly | Sophia Genetics downgraded to Equal Weight from Overweight at Morgan Stanley |
| June 27, 2024 6:20 am | Subbu Nambi | Guggenheim | $6.00 | $4.52 | StreetInsider | Guggenheim Starts Sophia Genetics SA (SOPH) at Buy |
| January 3, 2023 7:14 am | Mark Massaro | BTIG | $6.00 | $2.06 | TheFly | Sophia Genetics initiated with a Buy at BTIG |
Latest News for SOPH
SAN DIEGO and NEW YORK, April 16, 2026 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, today announced that the Mount Sinai Health System, one of the leading academic health systems in the United States, will adopt the AI-powered SOPHiA DDM™ Platform to advance cancer research and enhance genomic testing capabilities. Mount Sinai, a National Cancer…
Hims and Hers Health (NYSE: HIMS - Get Free Report) and SOPHiA GENETICS (NASDAQ: SOPH - Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings. Valuation and Earnings This table compares
SOPHiA GENETICS (NASDAQ: SOPH) executives highlighted accelerating commercial momentum, expanding platform capabilities, and improved profitability outlook during the company's fourth-quarter and full-year 2025 earnings call. Management also discussed leadership changes, major customer wins, and progress in both its clinical and biopharma businesses. 2025 performance and platform scale Co-founder and CEO Dr. Jurgi…
SOPHiA GENETICS SA (SOPH) Q4 2025 Earnings Call Transcript
BOSTON and ROLLE, Switzerland, March 3, 2026 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 Financial Results Revenue was $21.7 million, up 22% year-over-year Gross margin was 67.7% on a reported basis and 73.9% on an adjusted basis, compared to 68.2%…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SOPH.
U.S. House Trading
No House trades found for SOPH.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.